Sanara MedTech (SMTI) director awarded 5,308 restricted shares vesting in 2027

Rhea-AI Filing Summary

Mack Roszell III reported acquisition or exercise transactions in this Form 4 filing.

Sanara MedTech Inc. director Mack Roszell III received a grant of 5,308 shares of restricted common stock as equity compensation. The award was made at no cash price and increases his direct holdings to 21,842 shares.

The restricted stock will vest on the earlier of the company’s 2027 annual shareholder meeting or June 4, 2027, as long as he continues providing certain services to Sanara MedTech Inc. through that date. The grant was issued under the company’s 2024 Omnibus Long-Term Incentive Plan.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Mack Roszell III

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	5,308	$0.00	--

Holdings After Transaction: Common Stock — 21,842 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Restricted stock grant: 5,308 shares Grant price: $0.0000 per share Holdings after grant: 21,842 shares +1 more

4 metrics

Restricted stock grant 5,308 shares Common Stock grant on June 4, 2026

Grant price $0.0000 per share Equity compensation, not open-market purchase

Holdings after grant 21,842 shares Total direct common stock holdings after transaction

Vesting date Earlier of 2027 annual meeting or June 4, 2027 Restricted stock vesting condition tied to continued service

Key Terms

restricted stock, 2024 Omnibus Long-Term Incentive Plan, annual shareholder meeting

3 terms

restricted stock financial

"Represents shares of restricted stock granted by Sanara MedTech Inc."

Shares granted to an individual that carry limits on transfer or sale until certain conditions are met, such as staying with the company for a set time or hitting performance targets. Think of them as a locked gift that gradually opens; for investors they matter because they affect how many shares may enter the market later, signal management incentives and potential dilution, and reveal confidence in future company performance.

2024 Omnibus Long-Term Incentive Plan financial

"pursuant to the Sanara MedTech Inc. 2024 Omnibus Long-Term Incentive Plan."

annual shareholder meeting financial

"will vest on the earlier of (i) the date of the 2027 annual shareholder meeting"

A yearly gathering where a company’s owners (shareholders) and its leaders meet to review performance, approve key decisions like electing directors, and vote on issues such as executive pay or major policy changes. Think of it as an annual town hall for people who own part of the business: investors use it to ask questions, influence direction through votes, and gauge management’s plans and transparency, all of which can affect the stock’s outlook.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mack Roszell III

(Last) (First) (Middle)

1200 SUMMIT AVE

SUITE 414

(Street)

FORT WORTH TEXAS 76102

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Sanara MedTech Inc. [ SMTI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/04/2026		A		5,308(1)	A	$0	21,842	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares of restricted stock granted by Sanara MedTech Inc. (the "Issuer") to the reporting person pursuant to the Sanara MedTech Inc. 2024 Omnibus Long-Term Incentive Plan. The restricted stock will vest on the earlier of (i) the date of the 2027 annual shareholder meeting or (ii) June 04, 2027, provided that the reporting person is providing certain services to the Issuer through such date.

	/s/ Roszell Mack III	06/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Sanara MedTech (SMTI) report for Mack Roszell III?

Sanara MedTech reported that director Mack Roszell III received 5,308 shares of restricted common stock as a grant. The shares were awarded at no purchase price under the 2024 Omnibus Long-Term Incentive Plan and represent equity-based compensation, not an open-market stock purchase.

How many Sanara MedTech (SMTI) shares does Mack Roszell III hold after this grant?

Following the restricted stock grant, Mack Roszell III directly holds 21,842 shares of Sanara MedTech common stock. This total includes the newly granted 5,308 restricted shares, which are subject to vesting conditions tied to service through the earlier of the 2027 annual meeting or June 4, 2027.

When do the newly granted Sanara MedTech (SMTI) restricted shares vest?

The 5,308 restricted shares will vest on the earlier of Sanara MedTech’s 2027 annual shareholder meeting or June 4, 2027. Vesting is contingent on Mack Roszell III continuing to provide certain services to the company through that date, aligning the grant with ongoing board or service commitments.

Was cash paid for the Sanara MedTech (SMTI) shares granted to Mack Roszell III?

No cash was paid for these shares; the grant price per share was reported as 0.0000. The 5,308 shares of restricted common stock represent a compensation award under Sanara MedTech’s 2024 Omnibus Long-Term Incentive Plan rather than a traditional open-market stock purchase transaction.

Under which plan were the Sanara MedTech (SMTI) restricted shares granted?

The restricted shares were granted under the Sanara MedTech Inc. 2024 Omnibus Long-Term Incentive Plan. This plan allows the company to issue equity awards such as restricted stock to directors and other service providers, aligning their interests with long-term shareholder value through contingent share ownership.